PROCEPT BioRobotics Reports Strong Q3 2024 Financial Results

PROCEPT BioRobotics (NASDAQ: PRCT) announced significant revenue growth in Q3 2024, with total revenue reaching $58.4 million, reflecting a 66% increase year-over-year. This financial performance was supported by heightened demand for its robotic systems, particularly in the U.S., where the installed base grew by 64%. The successful launch of the HYDROS Robotic System played a critical role in this success despite initial challenges. Additionally, PROCEPT introduced a new clinical trial for Aquablation therapy and improved its net losses, indicative of strategic growth and a clear path toward profitability.

Key Takeaways

• PROCEPT BioRobotics reported a 66% increase in total revenue for Q3 2024, reaching $58.4 million.
• U.S. revenue was $52.2 million, a 62% increase, with the HYDROS Robotic System contributing 80% of new sales.
• International revenue grew by 86%, notably boosted by sales in the U.K.
• Gross margins reached a record high of 63.2%.
• Net loss narrowed to $21 million from $24.6 million the previous year.
• Full-year 2024 revenue is projected between $222.5 million and $223 million, with anticipated gross margins around 61%.

Company Outlook

• Expectations for 2024 revenue growth of 63% to 64%.
• Anticipate selling approximately 186 robotic systems by year-end 2024.
• Predict 88% increase in international revenue, reaching $22.4 million.
• Project operating expenses to rise by 29%, totaling $231.5 million.
• Full-year adjusted EBITDA loss expected around $60 million.

Bearish Highlights

• Year-over-year decline in utilization per account.
• Saline shortages and hurricane disruptions projected to impact procedure volumes.

Bullish Highlights

• Positive reception for the HYDROS system, with many launches planned for late 2024.
• Optimism surrounding expansion of treatment options for prostate cancer, including the ASC channel pilot program in 2025.
• Favorable reimbursement dynamics with Medicare and private payers like Humana and Cigna.

Misses

• Training of sales representatives on the HYDROS system may temporarily impact procedure volumes in Q4.
• Some procedures delayed in careful rollout of the HYDROS platform.

Q&A Highlights

• Discussions regarding ASP guidance and HYDROS rollout focusing on cost competitiveness and margin improvements.
• Emphasis on generating Level 1 data to support guideline inclusion for market expansion.

In summary, PROCEPT BioRobotics is successfully executing its growth strategy, showing strong financial performance in Q3 2024 and promising developments in its product offerings. The focus on expanding its market presence in prostate cancer treatment highlights their commitment to reaching profitability in 2024.